This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Roche will present data from five studies from the EVRYSDI clinicaldevelopment programme, which was designed to represent a broad spectrum of people living with SMA. The full range of data from Roche’s clinicaldevelopment programme in neuroscience being presented at 2021 AAN include: Medicine and/or Therapeutic Area.
Structure 3:1031-1039 (1995)
3 Waters J, Biocentury ; October 26, (2018)
4 NCT02273960; ClinicalTrials.gov ; “Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (ITP)”; results posted April 1, 2019, updated July 29, 2019 and accessed Jan 11, 2021
5 Ferrant JL et al., 1 Lederman, S. International Immunol. (11):1583
Based on these promising findings, Transgene intends to continue the clinicaldevelopment of TG4001 in a larger, controlled confirmatory study as we look to provide a better treatment option for this patient population,” added Dr. Maud Brandely, MD, PhD, Chief Medical Officer of Transgene.
Conclusions.
Based on preclinical studies, OCREVUS binds to CD20 cell surface proteinsexpressed on certain B cells, but not on stem cells or plasma cells, suggesting that important functions of the immune system may be preserved. The Phase III clinicaldevelopment programme for ENSPRYNG includes two studies: SAkuraStar and SAkuraSky.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content